BPC-157 Arginate (Oral)
Oral-marketed BPC-157 variant; clinical outcome evidence for this specific oral formulation is not established.
goal:gut-digestiongoal:gut-healthgoal:recovery-sorenessconstraint:not-drug-test-safeevidence:very-lowstudy:other-unclearpop:other-unclearform:liquid
Dosing model
FLATFixed dose (no body-weight scaling).
Min dose
—
Max dose
—
Rounding
—
Stacks containing BPC-157 Arginate (Oral)
Public community stacks that include this ingredient.
No public stacks include this ingredient yet.
Evidence
1 record
GI mucosal protection (general BPC-157 literature)
Mostly animal/in vitro • Mechanistic/animal (inference)
BPC-157 has preclinical GI model literature; this does not validate a specific marketed oral formulation in humans.
Dose: —
Forms
Liquid
Vendor listing: oral liquid format